"label","description","instanceType","id","uuid:ID","rationale","name"
"","The main design for the study","StudyDesign","StudyDesign_1","f6f97956-814b-403f-91af-2922bf3315ef","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1"
